CAS: 144222-22-0; 1-Boc-4-(Aminomethyl)Piperidine

相似化合物

359629-16-6 135632-53-0 7144-05-0

上下游产品

CAS号24424-99-5 二碳酸二叔丁酯 | CAS号7144-05-0 4-氨甲基哌啶 | CAS号325290-50-4 tert-butyl 4-(a... | CAS号452338-38-4 N-(1-tert-butox... | CAS号91419-52-2 N-B°C-4-氰基哌啶 | CAS号7646-93-7 硫酸氢钾 | CAS号1038352-48-5 (E)-tert-butyl ... | CAS号91419-48-6 N-B°C-4-哌啶甲酰胺 | CAS号77-92-9 柠檬酸 | CAS号155456-33-0 1-B°C-4-(CBZ-AM... | CAS号887581-75-1 1-B°C-4-[(2-BRO... | CAS号939986-79-5 4-[[(6-氯-4-嘧啶基)...

二碳酸二叔丁酯置于sodium Azide,三乙胺,三苯基膦体系中,用 四氢呋喃,甲醇,二氯甲烷,水,N,N-二甲基甲酰胺 用作溶剂,化学反应 16.0H,反应生成1-叔丁氧羰基-4-氨甲基哌啶
参考文献:发现新型 4-甲基哌啶基苯甲酰胺衍生物作为 5-Ht4 受体激动剂用于治疗胃肠道疾病
标题:发现新型 4-甲基哌啶基苯甲酰胺衍生物作为 5-Ht4 受体激动剂用于治疗胃肠道疾病
摘要:合成了新型 4-甲基哌啶基苯甲酰胺衍生物,并评估了体外和体内的促运动活性.在这些衍生物中,去甲西沙必利的 3-甲氧基哌啶部分,西沙必利的药效团和 Da-6650 被替换为没有手性中心的 4-甲基哌啶基部分.在这些衍生物中,化合物28B具有强效的 5-Ht 4受体结合亲和力 (Ic 50 = 0.067 μm),并且在不抑制 Cyp3A4 (Ic 50 = 7.272 μm) 和阻断人类 Ether-à-Go-Go-Related 的情况下提高了安全性基因 (Herg) 通道 (Ic 50 > 10 μm).体内大鼠模型,化合物28B与对照组相比,胃排空率提高 (68.2%),排便重量增加两倍以上.此外,它在刺激大鼠模型中显示出内脏超敏反应的缓解作用.因此,化合物28B被选为临床前候选药物,作为促动力剂,具有非常好的安全性,可用于治疗胃肠道疾病.
Doi:10.1002/bkcs.12667

专利信息

专利号:WO-2025101716-A1
优先权日:2023-11-07
标题:Processes for synthesis of trifunctionalized sulfur(vi) compounds
发明人：LOPCHUK JUSTIN; SHULTZ ZACHARY; ATHAWALE PARESH
权利人:H LEE MOFFITT CANCER CT & RES
摘要:This disclosure describes processes for the asymmetric synthesis of trifunctionalized sulfur(VI) containing organic compounds of Formula I and Formula VI, as well as compounds of Formula I and Formula VI prepared by the processes described.

专利号:US-2025129021-A1
优先权日:2023-09-19
标 题:Small molecule protein synthesis modulators
发明人：GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I), Formula (V)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

专利号:US-8933227-B2
优先权日:2009-08-14
标题 :Selective synthesis of functionalized pyrimidines
发明人：LINZ GUENTER; KRAEMER GERD; KUSSEROW SABRINA; SCHNAUBELT JUERGEN
权利人:LINZ GUENTER; KRAEMER GERD; KUSSEROW SABRINA; SCHNAUBELT JUERGEN; BOEHRINGER INGELHEIM INT
摘要:The present invention relates to a process for making 2,4-differentiated 5-trifluoromethyl pyrimidines and 2-amino-5-trifluoromethyl-pyrimidine derivatives, which compounds are useful in the preparation of pharmacologically active compounds.

专利号:US-9833457-B2
优先权日:2008-01-25
标题:Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
发明人：MJALLI ADNAN M M; GADDAM BAPU; POLISETTI DHARMA RAO; KOSTURA MATTHEW J; GUZEL MUSTAFA
权利人:VTV THERAPEUTICS LLC
摘要:The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to psoriatic arthritis.

专利号:WO-2025068371-A1
优先权日:2023-09-28
标 题:Inhibitors of the proprotein convertase furin, methods of production thereof and use
发明人：STEINMETZER TORSTEN; LANGE ROMAN WERNER; BOLLER CHARLOTTE; FRIEBERTSHÄUSER EVA; BLOCH KONSTANTIN
权利人:PHILIPPS UNIV MARBURG
摘要:The invention relates to novel inhibitors of the serine protease furin and to related furin-like proprotein convertases according to claim 1, and to methods of synthesis thereof and to use for production of medicaments for treatment of furin-dependent viral and bacterial infection diseases, and other disorders involving furin, such as cystic fibrosis, cancer, osteoarthritis, hypertension, and neurodegenerative disorders.

专利号:US-6320049-B1
优先权日:1997-08-05
标题 :Alpha 1a adrenergic receptor antagonists
发明人：SIDLER DANIEL R; LARSEN ROBERT D; LI WENJIE
权利人:MERCK & CO INC
摘要:This invention relates to crystalline pharmaceutically acceptable salts of an alpha 1a adrenergic receptor antagonist, Compound A, which are useful in the treatment of benign prostatic hyperplasia. Pharmaceutical compositions employing the crystalline salts, and processes for making and using the crystalline salts and pharmaceutical compositions of Compound A are also disclosed. This invention further relates to a process for obtaining enantiomerically pure intermediate useful for the synthesis of end product alpha 1a adrenergic receptor antagonists. The end product compounds are useful for the treatment of benign prostatic hyperplasia and for relaxing lower urinary tract tissue. The invention also relates to a process for preparing a class of dihydropyrimidinone compounds of which Compound A is a member, wherein the process involves deprotonating a dihydropyrimidinone compound and then coupling the deprotonated derivative with a primary amine.